EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage Model

Andrea Duminuco iD, Silvia Rita Vitale iD, Antonella Nardo, Patrick Harrington iD, Stefania Stella, Michele Massimino iD, Cristina Tomarchio iD, Elisa Mauro, Marina S Parisi, Cinzia Maugeri, Francesco Di Raimondo, Giuseppe A Palumbo iD und 2 weitere

Genes · 2026

DOI: 10.3390/genes17020218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2026. Verfasst von Andrea Duminuco und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hematology with BMT Unit, A.O.U. Policlinico "G. Rodolico-S. Marco", 95123 Catania, Italy. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute myeloid leukemia (AML) is genomically heterogeneous, and translating baseline molecular data into individualized prognosis remains difficult. We assessed real-world outcomes and externally validated the Sanger Institute AML multistage prognostic model.

Methods

This single-center, retrospective study included 73 AML patients who underwent targeted NGS profiling. In intensively treated patients, the published, validated Sanger AML multistage prognostic model was compared with observed 12- and 36-month clinical outcomes using quadratic-weighted Cohen’s kappa.

Results

Median age was 61 years, and median overall survival was 13 months, with the most significant survival differences driven by treatment intensity. TP53 mutations occurred in 7 patients (9.6%) and were linked to primary refractoriness and extremely poor survival. TP53 was the only independent predictor of death (HR 8.07, 95% CI 2.23–29.13; p = 0.0014). Model concordance was moderate at 12 months (29 evaluable cases; weighted κ = 0.52; alive/dead κ = 0.52) and fair-to-moderate at 36 months (23 cases; weighted κ = 0.46). The tool performed best for predicted death without remission, while most discrepancies involved patients expected to remain in first remission who later relapsed and died.

Conclusions

TP53 disruption dominates prognosis in real-world AML. The multistage tool supports early high-risk identification but shows limited long-term calibration, motivating the development of dynamic models integrating contemporary therapies and longitudinal min/serial NGS data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteTumor Suppressor Protein p53HumansPrognosisFemaleMiddle AgedMaleMutationGenomicsRetrospective StudiesAgedAdultHigh-Throughput Nucleotide SequencingAged, 80 and over

Stichwörter der Autor:innen

Sangel AML modelTP53acute myeloid leukemianext-generation sequencingprognosis

Substanzen

Tumor Suppressor Protein p53TP53 protein, human

Autor:innen und Institutionen

  • Hematology with BMT Unit, A.O.U. Policlinico "G. Rodolico-S. Marco", 95123 Catania, Italy.
  • Center of Experimental Oncology and Hematology, A.O.U. Policlinico "G. Rodolico-S. Marco", 95123 Catania, Italy.
  • Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK.
  • Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
  • Department of General Surgery and Medical-Surgical Specialties, University of Catania, 95123 Catania, Italy.
  • Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), University of Palermo, 90128 Palermo, Italy.

ORCID-Profile: Andrea Duminuco, Silvia Rita Vitale, Patrick Harrington, Michele Massimino, Cristina Tomarchio, Giuseppe A Palumbo, Calogero Vetro

Zitieren

APA

Duminuco, A., Vitale, S. R., Nardo, A., Harrington, P., Stella, S., Massimino, M., Tomarchio, C., Mauro, E., Parisi, M. S., Maugeri, C., Di Raimondo, F., Palumbo, G. A., Manzella, L., & Vetro, C. (2026). Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage Model. Genes. https://doi.org/10.3390/genes17020218

Vancouver

Duminuco A, Vitale SR, Nardo A, Harrington P, Stella S, Massimino M, et al. Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage Model. Genes. 2026. doi:10.3390/genes17020218

BibTeX
@article{Duminuco2026,
  author = {Duminuco, Andrea and Vitale, Silvia Rita and Nardo, Antonella and Harrington, Patrick and Stella, Stefania and Massimino, Michele and Tomarchio, Cristina and Mauro, Elisa and Parisi, Marina S and Maugeri, Cinzia and Di Raimondo, Francesco and Palumbo, Giuseppe A and Manzella, Livia and Vetro, Calogero},
  title = {Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage Model},
  journal = {Genes},
  year = {2026},
  doi = {10.3390/genes17020218}
}
Kostenlos starten →